Astrazeneca earnings were $10.4B for the trailing 12 months ending Mar 31, 2026, with 33.9% growth year over year. The latest AZN earnings report on Mar 31, 2026 announced Q1 2026 earnings of $3.1B, up 32.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AZN reported annual earnings of $10.2B, with 45.3% growth.
AZN past earnings growth
How has AZN's earnings growth performed historically?
Astrazeneca (NYSE: AZN) reported Q1 2026 earnings per share (EPS) of $1.99, up 5.85% year over year. Total AZN earnings for the quarter were $3.08 billion. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $1.88.
As of the last Astrazeneca earnings report, Astrazeneca is currently profitable. Astrazeneca's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $10.39 billion, a 33.67% increase year over year.
What was AZN's earnings growth in the past year?
As of Astrazeneca's earnings date in Q2 2026, Astrazeneca's earnings has grown 33.93% year over year. This is 88.74 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 122.67%. AZN earnings in the past year totalled $10.39 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.